Antihyperlipidaemic activity of swertiamarin, a secoiridoid glycoside in poloxamer-407-induced hyperlipidaemic rats.
We have investigated antihyperlipidaemic effect of swertiamarin (50 mg/kg, oral once) isolated from the perennial herb Enicostemma littorale Blume in poloxamer 407 (P-407)-induced hyperlipidaemic rats. Rats were made hyperlipidaemic by intraperitoneal administration of P-407 (400 mg/kg). Serum lipid levels such as total cholesterol, triglycerides and low-density lipoprotein cholesterol increased significantly (P < 0.001) compared with normal control rats. All these changes were significantly prevented in the rats treated with swertiamarin. Serum high-density lipoprotein (HDL) cholesterol was found to be reduced in the P-407 control rats. However, administration of swertiamarin significantly (P < 0.01) increased HDL levels and it showed a significant lipid-lowering effect, as well as a high antiatherogenic potential. Overall swertiamarin is an effective lipid-lowering lead compound and can be useful for preventing atherosclerosis.
Vaidya
Hitesh
H
Department of Pharmacology, L. M. College of Pharmacy, Navrangpura, Ahmadabad, Gujarat 380009, India.
Rajani
Mandapati
M
Sudarsanam
Vasudevan
V
Padh
Harish
H
Goyal
Ramesh
R
D000818:Animals; D005960:Glucosides / Q000494:pharmacology*; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D057888:Iridoid Glucosides; D039823:Iridoids / Q000494:pharmacology*; D008297:Male; D020442:Poloxamer / Q000494:pharmacology*; D011753:Pyrones / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D005960:Glucosides; D000960:Hypolipidemic Agents; D057888:Iridoid Glucosides; D039823:Iridoids; D011753:Pyrones; D020442:Poloxamer; C013270:swertiamarin